Clinical trials: Acute Ischemic Stroke
Stroke, Stroke Acute
Research on the Effectiveness of Neurorehabilitation After Stroke
This clinical trial aims to investigate the effectiveness of a novel neurorehabilitation technology for treating stroke in adults.
- Conditions
- Stroke, Stroke Acute, Stroke with Hemiparesis, Stroke, Acute
- Trial name
- NCT06753006
- Testing
- Neurorehabilitation simulator, Standard course
- Where
- Russia
- Volunteers
- 44 people
- Sponsor
- Neurotechnika
Stroke
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5…
- Trial name
- NCT05395351
- Testing
- rt-PA
- Where
- China
- Volunteers
- 113,035 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke
Prospective, single-arm, multicenter, observational registry of the ACE Reperfusion Catheters and the Penumbra System in Europe.
- Trial name
- PROMISE (NCT02678169)
- Testing
- Penumbra Aspiration System
- Where
- Germany
- Volunteers
- 204 people
- Sponsor
- Penumbra Inc.
Ischaemic Stroke
The RETRAIN Trial Phase 2
Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom.
- Trial name
- RETRAIN 2 (NCT07197996)
- Testing
- Intermittent Pneumatic Compression, geko® T3
- Where
- United Kingdom
- Volunteers
- 53 people
- Sponsor
- Firstkind Ltd
Acute Ischemic Stroke (AIS)
Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
- Trial name
- ARPEGGIO (NCT05585606)
- Testing
- scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- Silver Creek Pharmaceuticals
Acute Ischemic Stroke AIS
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke
- Trial name
- STEVIA (NCT06995625)
- Testing
- SNE-101
- Where
- 3 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- S&Ebio Co. Ltd.
Acute Ischemic Stroke
DAISe 1 Feasibility Study to Evaluate the DAISe Thrombectomy System for Acute Ischemic Stroke
The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 36 subjects. The maximum enrollment is 10 subjects per site. A maximum of 6 investigational centers in Europe will participate.
- Trial name
- NCT05139147
- Testing
- DAISe Thrombectomy System
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- MIVI Neuroscience, Inc.
Acute Ischemic Stroke
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical…
- Trial name
- HEMERA-1 (NCT04677777)
- Testing
- PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Prolong Pharmaceuticals
Stroke, Acute
Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin
The purpose of the Stroke AF study is to compare the incidence of atrial fibrillation (AF) through 12 months between continuous cardiac rhythm monitoring with the Reveal LINQ™ Insertable Cardiac Monitor (ICM) (continuous…
- Trial name
- NCT02700945
- Testing
- Reveal LINQ™ Insertable Cardiac Monitor
- Where
- 35 sites in United States
- Volunteers
- 496 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Stroke, Ischemic
A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ⅱb/Ⅲ clinical study to evaluate the efficacy and safety of XY03-EA tablets, a novel oral neuroprotective agent, and explore the…
- Trial name
- XY03-EA (NCT06755944)
- Testing
- XY03-EA 150 mg (per dose), XY03-EA 300 mg (Regimen A), XY03-EA 300 mg (Regimen B)
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Ischemic Stroke, Acute
Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus…
- Trial name
- FRIDA-CT (NCT07324837)
- Testing
- non-immunogenic staphylokinase
- Where
- 17 sites in Russia
- Volunteers
- 990 people
- Sponsor
- Supergene, LLC
Stroke
Study to Assess the Safety and Effectiveness of the Penumbra System
This clinical evaluation is a prospective, single-arm, multi-center trial. The purpose of this clinical evaluation is to assess the safety and effectiveness of the Penumbra System in the revascularization of patients presenting…
- Trial name
- NCT00334061
- Testing
- Penumbra System
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Penumbra Inc.
Acute Ischemic Stroke
A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke
The goal of this clinical trial is to learn if AB126, an investigational treatment made from neural exosomes, is safe and well tolerated when given to adults with moderate to severe acute ischemic stroke (AIS) who have undergone…
- Trial name
- NEXIS (NCT07813130)
- Testing
- AB126 Neural Exosomes Intravenous Injection
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aruna Bio, Inc.
Stroke
Acute Recanalization of Thrombo-Embolic Ischemic Stroke With pREset (ARTESp)
ARTESp is a prospective multicenter study in which the pREset thrombectomy system (phenox GmbH* Germany) will be examined. The effectiveness, safety and the long-term success when using the pREset to treat acute occlusions of…
- Trial name
- ARTESp (NCT02437409)
- Testing
- pREset thrombectomy retriever
- Where
- 4 sites in Germany
- Volunteers
- 115 people
- Sponsor
- Phenox GmbH
Acute Ischemic Stroke
Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
This is a randomized, double-blinded, placebo-controlled study investigating the safety and efficacy of QD202 injection in patients with acute ischemic stroke undergoing thrombolysis excluding endovascular thrombectomy.
- Trial name
- NCT07581210
- Testing
- QD202
- Where
- 14 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai QuietD Biotechnology Co., Ltd.
Stroke, Stroke, Acute
Phase 1 Study to Assess AER-271
The objective of this Phase 1 trial is to assess the safety, tolerability and pharmacokinetics of AER-271 in health subjects.
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic
- Trial name
- NCT03804476
- Testing
- AER-271
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Aeromics, Inc.
Ischemic Stroke
Safety, Tolerability and Pharmacokinetics of SP-8203
Phase I study in health volunteers to assess the safety, tolerability and pharmacokinetics of escalating single doses and multiple doses of SP-8203
- Trial name
- NCT01757795
- Testing
- SP-8203
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness
This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.
- Trial name
- C-REGS2 (NCT03480698)
- Testing
- Cerebrolysin
- Where
- 8 sites in Austria
- Volunteers
- 1,851 people
- Sponsor
- Ever Neuro Pharma GmbH
Acute Coronary Syndromes (ACS), Recent Myocardial Infarction
The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants
CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes.
- Conditions
- Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
- Trial name
- NCT07619885
- Testing
- CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Shanghai CureGene Pharmaceutical Co., Ltd.